Syros to Present New Preclinical Data on SY-1365 in Ovarian Cancer at Upcoming AACR Annual Meeting
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to
control the expression of genes, today announced that the Company and its collaborators from the Dana-Farber Cancer Institute will
present new preclinical data on SY-1365, a first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor currently in a Phase
1 trial in patients with advanced solid tumors, at the American Association for Cancer Research (AACR) Annual Meeting taking place
April 14-18, 2018 in Chicago.
The data, which will be presented in both a poster discussion session and a poster session, show that SY-1365 has significant
anti-tumor activity in multiple models of treatment-resistant ovarian cancer. The data also identify potential biomarkers of
response to SY-1365. Syros plans to open expansion cohorts in mid-2018 in its ongoing Phase 1 trial to evaluate SY-1365 in patients
with ovarian cancer, as well as to evaluate these potential biomarkers (ClinicalTrials.gov identifier: NCT03134638).
Details on the presentations are as follows:
Presentation Title: SY-1365, a selective CDK7 inhibitor, exhibits potent anti-tumor activity against ovarian cancer models in
vitro and in vivo
Session Category: Molecular and Cellular Biology/Genetics
Presenter: Panagiotis A. Konstantinopoulos, M.D., Ph.D., Dana-Farber Cancer Institute
Abstract Number: 1343
Poster Discussion Session
Date & Time: Sunday, April 15, 4:00 p.m. - 5:00 p.m. CDT
Session Title: Targeting the Cell Cycle: Mechanism and Therapy – Poster Discussion
Location: McCormick Place South, Level 4, Room S402
Poster Session
Date and Time: Monday, April 16, 8:00 a.m. - 12:00 p.m. CDT
Session Title: Targeting the Cell Cycle: Mechanism and Therapy
Poster Session Location: McCormick Place South, Exhibit Hall A, Poster Section 23
About Syros Pharmaceuticals
Syros is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control
expression of genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this
unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient
populations. Because gene expression is fundamental to the function of all cells, Syros’ gene control platform has broad potential
to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and
monogenic diseases and is advancing a growing pipeline of gene control medicines. Syros’ lead drug candidates are SY-1425, a
selective RARα agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and
myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor in a Phase 1 clinical trial for patients with advanced solid
tumors. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge,
Mass.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995,
including without limitation statements regarding the Company’s ability initiate expansion cohorts in the Phase 1 clinical trial of
SY-1365 in ovarian and breast cancer in mid-2018, whether potential biomarkers of response to SY-1365 will result in a successful
patient selection strategy, and the benefits of Syros’ gene control platform. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’
‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’
‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Actual results or events could differ materially from the plans,
intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including
Syros’ ability to: advance the development of its programs, including SY-1365, under the timelines it projects in current and
future clinical trials; demonstrate in any current and future clinical trials the requisite safety, efficacy and combinability of
its drug candidates; replicate scientific and non-clinical data in clinical trials; successfully develop a companion diagnostic
test to identify patients with predictive biomarkers; obtain and maintain patent protection for its drug candidates and the freedom
to operate under third party intellectual property; obtain and maintain necessary regulatory approvals; identify, enter into and
maintain collaboration agreements with third parties, including its ability to perform under the collaboration agreement with
Incyte; manage competition; manage expenses; raise the substantial additional capital needed to achieve its business objectives;
attract and retain qualified personnel; and successfully execute on its business strategies; risks described under the caption
“Risk Factors” in Syros’ Annual Report on Form 10-K for the year ended December 31, 2017, which is on file with the Securities and
Exchange Commission; and risks described in other filings that Syros makes with the Securities and Exchange Commission in the
future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Syros expressly
disclaims any obligation to update any forward-looking statements, whether because of new information, future events or
otherwise.
Media Contact:
Syros Pharmaceuticals
Naomi Aoki, 617-283-4298
naoki@syros.com
or
Investor Contact:
Stern Investor Relations, Inc.
Hannah Deresiewicz, 212-362-1200
hannahd@sternir.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20180314005997/en/